Zidovudine (3' -azido-3' -deoxythymidine, azidothymidine) has demonstrated clinical efficacy in patients with acquired immunodeficiency syndrome (AIDS) and related disorders but toxicity often limits its use.
Introduction
A considerable number of compounds have been demonstrated to have an activity against human immunodeficiency virus type 1 (HIV-1) in vitro , the aqent responsible for acquired immunodeficiency syndrome (AIDS) Levy, 1988; Hirsch, 1989) .
So far only zidovudine (also called 3'-azido-3'-deoxythymidine, azidothymidine or AZl) has been shown to reduce morbidity and mortality in patients with AIDS and AIDS-related complex in a multicentre, placebo-controlled double-blind study . Furthermore, early treatment with zidovudine of asymptomatic HIV-1 seropositive patients with low numbers of CD4positive cells has resulted in a significant delay in disease progression (Volberding et al., 1990) .
Side-effects, mainly bone marrow toxicity, are frequent, however, and lead to reduction in dosage and interruption of treatment in more than half of the patients Dournon etal., 1988) .
Since it is known that zidovudine is rapidly cleared from the plasma, the drug is generally administered every 4-6 h and both the necessity for frequent dosing and toxicity severely impair patients' compliance.
Approaches to reduce zidovudine-induced toxicity have been evaluated in vitro and also in limited clinical trials. Using zidovudine in vitro in combination with a synergistic partner compound, such as recombinant interferon-alpha-A or acyclovir, offers the theoretical possibility of reducing the dose of zidovudine with sustained antiviral potency Surbone et al., 1988) . Unfortunately daily doses as low as 500 mg zidovudine combined with interferon-alpha-A have exhibited considerable haemopoietic toxicity (Baumann, 1989) .
In this report we wanted to evaluate and compare the antiviral effect and cytotoxicity of one single daily zidovudine pulse exposure with continuous exposure in HIV-1 . and HIV-2 infected cells. Concentrations of the drug were chosen according to the results of a computer simulation model of achievable plasma levels with single-day oral therapy schedules,
Results

Effect of zidovudine pulse exposure and continuous zidovudine therapy on HIV-1 replication
Experiment 1 was designed to determine possible antiviral effects and cytotoxicity of various daily 50-min pulse exposures of zidovudine in comparison to continuous exposure to 0.1 fLM zidovudine for a period of 7 days. Daily zidovudine pulses of 5 fLM inhibited HIV replication in peripheral blood mononuclear cells (PBMC) as effectively as 0.1 fLM continuous zidovudine, whereas pulses of 0.1 fLM and 1 fLM were only partially effective (fable 1). No cytotoxicity was observed in cultures treated either with pulse regimens or continuous therapy. Experiment 4 ( Fig. 1a ) was carried out in triplicate cultures. HIV-1 infected PBMC were exposed for 4 days to either 60-min pulses of 10 f.LM zidovudine or to continuous concentrations of 1 f.LM zidovudine. No HIV-1 p24 antigen could be detected at Day 7 in pulse-treated cultures and at Day 10 in cultures exposed to continuous zidovudine. At Day 10 p24 expression was still more than 100-fold lower in pulse cultures compared to the infected untreated controls. Antiviral effect of 4 days' exposure was lost after 10 days' culture in drug-free medium.
Effect of zidovudine pulse exposure and continuous zidovudine therapy on HIV-2 replication
Experiment 5 Was carried out as Experiment 4 with the following exceptions: HIV-2 (LAV-2) was used, cultures were performed in duplicate and maintained for 23 days. Both pulse therapy with 10 f.LM zidovudine and continuous therapy with 0.1 f.LM and 1 f.LM led to undetectable HIV-2 expression for over 14 days with no toxicity (Fig. 1b ). Thus both approaches induced a significant and comparable HIV-2 suppressive effect for over 10 days in the absence of zidovudine.
Experiment 6 was identical but C8166 (CD4-positive) cells were used. Replication was assessed at Days 2, 4 and 7. Zidovudine pulse exposure with 10f.LM was as effective as 1 f.LM continuous therapy, whereas continuous therapy with 0.1 f.LM was clearly less effective.
Quantification of zidovudine anabolism in continuous and pulse regimens
PBMC cultures were exposed to 10 f.LM [3Hjzidovudine for 60 min and to 1 f.LM [3Hjzidovudine for 24h. The results show that pulse exposure to 10 f.LM zidovudine leads to intracellular levels of zidovudine triphosphate that are comparable to those observed in the continuous regimen ( Table 2) .
The efficiency of removing zidovudine from cultures previously exposed to 10 f.LM zidovudine for 60 min was tested. No measurable zidovudine was detectable in the culture supernatants. Therefore a possible carry over of zidovudine in amounts with resulting antiviral activity by insufficient washing can be excluded.
Effectiveness combined with negligible toxicity and minimal side-effects arethe major goals of any drug therapy. In HIV-infected patients oral bioavailability, easyadministration and low treatment costs will become increasingly important, considering the long-term treatment involved. In Experiment 2 the lowest effective 60-min pulse concentration to inhibit HIV-1 replication was found to be 2 f.LM (Table 1) . Equally, no HIV-1 replication could be detectedat Day 7 in cultures treated continuously with 0.1 and 1 f.LM zidovudine until Day 4.
Discussion
In Experiment 3, PBMC cultures were exposed once a day for a period of only 30 min to 5, 10 and 20 f.LM zidovudine or to continuous concentrations of 0.1 and 1 f.LM zidovudine. Up to Day 10, HIV-1 replication was inhibited equally well with pulse regimens or continuous therapy. At Day 14 (10 days without zidovudine), only continuous therapy with 1 f.LM zidovudine from Day 1 to 4 revealed a residual antiviral effect. No cytotoxicity was seen in any cultures at Day 7. At Day 10, cell counts were slightly reduced in all cultures exposed to zidovudine (range 1.36-1.82 x 10 6/ml) compared to the untreated control (2.44 x 10 6/ml). Treated cultures displayed no Based on the rapid clearance of zidovudine in humans, the drug is currently administered every 4-6 h to maintain minimal trough plasma levels that are in vitro virucidal (Yarchoan et aI., 1986; Klecker et aI., 1987; .
The drug is only active as an inhibitor of HIV reverse transcriptase after intracellular phosphorylation to its triphosphate form (zidovudine-TP) by cellular enzymes (Furman et aI., 1986; St. Clair et a/., 1987) . Since the intracellular clearance of zidovudine-TP was reported to be considerably longer than the plasma clearance of zidovudine (Furman et a/., 1986) in vitro, we reasoned that twice or single daily exposure to zidovudine could lead to sufficient levels of intracellular zidovudine-TP to suppress viral replication. In the absence of human pharmacokinetic data computer-simulation of pharmacokinetic profiles was performed and subsequently showed that a 1 g oral dose of zidovudine is sufficient to yield plasma concentrations of 10 J.LM for at least 1 h (Fig. 2) . The study design was therefore believed to be realistic.
The results of our in vitro experiments show that replication of HIV-1 and HIV-2 is efficiently inhibited by both the pulse and the conventional regimen. The observation that adequate intracellular pools of zidovudine-TP were achieved by both treatment modes supports the finding of adequate antiviral activity (Table2). The fact that lower pulse concentrations than 10 f.LM, e.g. 2-5 J.LM, also showed an antiviral effect even suggests that single daily doses in the range of 500 mg might be efficacious.
Although the results of studies in Vitro must be interpreted cautiously, the results we report here suggest that clinical trials with single daily doses of zidovudine should be performed. Such a trial is currently being started in our institution.
Materials and Experimental procedures
Compound 3' -azido-3'-deoxythymidine and FH]3' -azido-3'-deoxythymidine were obtained from Wellcome Research Laboratories Zidovudine (prnoVl0 6 cells) after 24 h" 
Experimental outline
A total of six different experiments were carried out, four with . HIV-1 and two with HIV-2 infected cells (Table 3) . Three-to four-day-old PHA-P-stimulated PBMC (Exps 1-5) from different donors and C8166 cells (Exp. 6) were exposed to HIV-1 (105 TCID sol1 0 6 cells) or HIV-2 (105TCID sol1 0 6 cells) for 60 min at 37°C! and washed twice with RPMI-1640 medium to remove residual I extracellular virus. Immediately thereafter cultures of 3 ml (10 6 I cells/ml) were exposed to appropriate concentrations of zidovu-i dine ( Table 3) either for 60 or 30 min once a day or continuously. i Cultures exposed to zidovudine for 60 or 30 min (pulse therapy) ! I were subsequently washed and maintained in drug-free medium! for 23 h. Cultures were then again exposed to zidovudine for 60 or i 30 min and the previous procedure was repeated as long as zidovudine exposure was planned.
Since the daily washing procedure could possibly influence HIV replication, cultures on continuous therapy and infected controls were washed identically. Cultures on continuous therapy were immediately re-exposed to the previous zidovudine concentration thereafter. Both culture sets were thus always handled in a comparable manner.
After completion of 4 days zidovudine exposure (7 days in Experiment i), cells were washed twice and subsequently cultured in drug-free medium for another 7-22 days to assess the long-term antiviral effect of previous zidovudine regimens. Culture media were changed every 3-4 days and cell concentrations adjusted to 1 x 10 6 cells/ml. Viable cell numbers were determined .
HIV-1 (HTLV-IIIB) was provided by R. C. Gallo, NCI, Bethesda, MD. HIV-1 virus stocks were prepared from the supernatant of an acutely infected H9 cell culture. Small aliquots were frozen at -70°C until used. Viral inoculum (50% tissue culture infectious doses, TCIDso) was titrated on H9 and C8166 cells as described previously (Vogt et a/., , 1988 . HIV-2 (LAV-2) was provided by F. Barre-Sinoussl. Virus stocks were prepared from superna-. tant of an HIV-2-infected CEM cell culture. Virus titration methods . were identical for HIV-1 and HIV-2. o Cultures were carried out as described previously (Vogt et a/., , 1988 . Briefly, PBMC were isolated by Ficoll-Hypaque sedimentation from venous blood of HIV-1 seronegative healthy blood donors. PBMC were subsequently stimulated with phytohaemagglutinin-P (PHA-P) (2JLg/ml) for 2 days and maintained in RPMI-1640 medium (Gibco, Life Technologies, Grand Island, NY) supplemented with 10% interleukin-2 (200 U/ml; Boehringer, Mannheim, Germany), 20% foetal bovine serum (Inotech, Wohlen, Switzerland) and L-glutamine (2mM; Gibco, BRL AG, Basle, Switzerland). Antibiotics were omitted in all experiments.
C8166 cells (CD4-positive) were a gift from B. Walker, Mass. General Hospital, Boston, MA and CEM cells were kindly provided by F. Barre-Sinoussi, Pasteut, Paris, France. C8166 and' CEM cells were maintained in the above medium without the addition of interleukin-2. for all cultures immediately after completion of zidovudine treatment and every 3-4 days thereafter using trypan blue exclusion, as described previously .
Assessment of HIV replication
Cultures were assayed in 3-4 day intervals from Day 4 up to Day 26 for HIV-1 p24 expression (HIV-p24 radioimmunoassay; DuPont, Wilmington, DE) and reverse transcriptase activity (Rl), as described previously (Vogt et al., , 1988 . Cell viability was determined for each culture at each medium change. All assay results were corrected for viable cell numbers.
Intracellular zidovudine anabolism
A duplicate set of cultures of uninfected PBMC was either incubated with 10 JLM zidovudine for 60 min or 1 JLM zidovudine for 24 h in the presence of 45 JLCi FHlzidovudine (45 uCi/nmof). After 60 min, cultures containing 10 JLM zidovudine were washed and exposed to zidovudine-free medium. Twenty-three hours later, cells of all cultures were washed twice with ice-cold phosphatebuffered saline. Trichloroacetic acid extracts of FHlzidovudinetreated cells were prepared according to a published procedure (Balzarini et aI., 1988) . Subsequently neutralized cell extracts were analysed by Paired Ion HPLC using a Nova Pack C18 steel column (3.9mm x 15 em) and PIC A ion-pairing reagent (Waters, Milford, MA). Zidovudine and its phosphorylated derivatives were eluted with a linear gradient from 5% to 30% acetonitrile in PIC A buffer over 15 min at a flow rate of 1.5ml min-1. Appropriate fractions of the eluate were collected and associated radioactivity was assayed by liquid scintillation counting. Furthermore, the efficiency of washing cells was tested to exclude possible carry over of zidovudlne. Aliquots of washed cultures were examined for residual zidovudine using an radioimmunoassay (ZDV-TracTM, 1251-RIA; IncstarCorp., Stillwater, MI; lower cut-off < 0.02 JLM) according to the manufacturers directions.
Pharmacokinetic profiles of zidovudine
The computer program SIPHAR (SIMED; 9-11 rue G. Enesco 94008 Creteil, France) was used to simulate the plasma zidovudine concentrations after a hypothetical 1 g p.o. dose (performed by Dr B. C. Weatherley, Wellcome Research Laboratories, Beckenham, Kent, UK).
